Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
The latest update is out from Organon ( (OGN) ).
Organon & Co. announced that the FDA has extended the review date for VTAMA® cream, used for treating atopic dermatitis, to March 12, 2025, without raising safety concerns. This extension impacts the company’s financial outlook for 2025, with expected revenue contributions and potential effects on earnings. Organon remains confident in the cream’s efficacy and is committed to providing the FDA with necessary information for approval.
See more data about OGN stock on TipRanks’ Stock Analysis page.
